Builds on vision to combine techniques for boosting the body’s natural tumour-fighting mechanisms with AI/machine learning technology
- GEDiCube, an AI/ML platform that combines differential molecular capabilities with multi-omic analysis to detect cancer early, to join NVIDIA Inception
- Initial focus is on pancreatic cancer: upcoming clinical trials will be an innovative multi-modal approach to building a predictive model
AMSTERDAM–(BUSINESS WIRE)–GEDiCube announced that it is joining NVIDIA Inception, a program which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
“This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” said Craig Rhodes, GEDiCube’s Chief Executive Officer. “NVIDIA’s advanced medical imaging capabilities with GEDiCube’s existing multi-omic AI system will help create an algorithm that pulls from both the imaging and omic modals. This will help our scientists understand the radiology and pathology imaging data alongside multi-omic data, thus enabling a better analysis of cancer.”